Study of CRD-4730 for CPVT (rare heart rhythm disorder)
Part of Heart & circulation clinical trials.
This study tests an experimental drug called CRD-4730 for people with CPVT, a rare inherited heart rhythm disorder that can cause dangerous fast heartbeats during exercise or stress. The trial will see if the drug can help control these abnormal heart rhythms better than current treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You have a confirmed diagnosis of CPVT (a rare heart rhythm condition) with a known genetic cause (RYR2 mutation).
- You can do a treadmill or bike test that shows frequent extra heartbeats (at least 10 per minute) or a certain heart rhythm pattern.
- You are on a stable dose of at least one heart medication (like a beta blocker, but not amiodarone) for at least 4 weeks before the study starts.
- You do not have other serious heart problems (like heart failure, blocked arteries, or a recent heart attack or stroke).
- You are willing to follow contraceptive rules if you are able to have children.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called AGP100 for people with CPVT, a genetic heart condition that causes dangerous heartbeats during exercise. The goal is to see if AGP100 can safely reduce these abnormal heart rhythms.
This trial tests a new gene therapy called SGT-501 for people with a genetic heart condition called CPVT, which can cause dangerous fast heartbeats. The goal is to see if the treatment can reduce these episodes.
This study is evaluating a new diagnostic test for Calcium Release Deficiency Syndrome (CRDS) and related heart rhythm disorders. It aims to find out if this test can accurately identify patients with these conditions, which could lead to better diagnosis and treatment.
This study looks at the risk of a fast heart rhythm (ventricular tachycardia) in people with genetic heart muscle diseases. It tests whether having a specific genetic change affects the success of a heart ablation procedure.
This study tests two different medicines to see if giving them early can prevent your heart from weakening over time when you have frequent extra beats. You may join if you have no symptoms from these beats and your heart function is still normal.
This Phase 1 trial tests RP-A601 (a gene-delivery type treatment) to see if it can reduce dangerous heart rhythm problems in people with PKP2-related arrhythmogenic cardiomyopathy (ACM). Because it’s an early safety/dose study, the main goal is to check safety and how the body responds.
Hear when a new Catecholaminergic Polymorphic Ventricular Tachycardia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.